Pipeline Programs↗
Distinct drugs in development (Preclinical–Phase 3)
Indications↗
Distinct diseases across all programs
Clinical Trials↗
All sponsored trials (all statuses)
Pipeline
By Phase
8 drugs in development
By Therapeutic Area
top 2
R&D Momentum
70/100
Pipeline Velocity
25/100
Trial Completion Rate
75/100
Pipeline Concentration
80/100
Pipeline Freshness
53/100
Strategic Signals
Activity
Last 14 days
A Phase III Randomized Trial of Protons Versus Photons for Hepatocellular Carcinoma
Phase III IGRT and SBRT vs IGRT and Hypofractionated IMRT for Localized Intermediate Risk Prostate Cancer
Radiotherapy With Concurrent Cetuximab vs. Carboplatin and Paclitaxel in Patients With Locoregionally Advanced Head and Neck Cancer With a Contraindication to Cisplatin: A Pragmatic Phase III Randomized Trial (CONCISE)
Managing Symptoms and Psychological Distress During Oral Anti-Cancer Treatment (SYMON)
Randomized Phase II/III Trial of Radiation With Cisplatin at 100 mg/m2 Every Three Weeks Versus Radiation With Weekly Cisplatin at 40 mg/m2 for Patients With Locoregionally Advanced Squamous Cell Carcinoma of the Head and Neck (SCCHN)
The Phase III 'High Five Trial' Five Fraction Radiation For High-Risk Prostate Cancer
A Phase II Trial of HER2-Targeted Therapies for Recurrent, Metastatic, or Unresectable HER2-Expressing Salivary Gland Cancers
Randomized Phase II Stereotactic Ablative Radiation Therapy (SABR) for Metastatic Unresected Renal Cell Carcinoma (RCC) Receiving Immunotherapy (SAMURAI)
The Phase III Adaptive Radiation and Chemotherapy for Muscle Invasive Bladder Cancer Trial (ARCHER)
Details
Company Overview
—
Mkt Cap
—
Revenue
—
Cash
Pipeline
Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)